Home/Get Matched/NCT05615779
Recruiting
View on ClinicalTrials.gov

Testing Randomized B-fructan diet against a placebo for inflammatory bowel diseases

Official title: Personalized B-fructan Diet in Inflammatory Bowel Disease Patients

The Fibre Study: RCT of Personalized Fibre Diet in IBD

Condition: Inflammatory Bowel DiseasesSponsor: University of ManitobaTarget enrollment: 600
  • 4 groups
  • Sites in Edmonton and Winnipeg
  • Recruiting
University of Alberta Hospital, Edmonton, AlbertaHealth Sciences Centre Hospital, Winnipeg, Manitoba

Interventions (4)

  • Other intervention

    Placebo Comparator: Randomized pectin diet

    UC and healthy control participants randomized to receive recommendations provided by a dietician increasing consumption of foods high in pectin

  • Other intervention

    Randomized B-fructan diet

    UC and healthy control participants randomized to receive recommendations provided by a dietician increasing consumption of foods high in B-fructan

  • Other intervention

    Personalized pectin diet

    UC and healthy control participants to receive recommendations provided by a dietician increasing consumption of foods high in pectin based on personal host (biopsy) and microbe (stool) response at baseline

Canadian Sites (2)

2 of 2 recruiting

  • University of Alberta Hospital

    Edmonton, Alberta

    Recruiting
  • Health Sciences Centre Hospital

    Winnipeg, Manitoba

    Recruiting

Eligibility Criteria

See who this study is looking for19 criteria

The trial’s own eligibility text, word for word from the registry. Only the trial site can say who takes part.

Inclusion

  • +Children (age 6-17) or young adults (age 18-39).
  • +Known or suspected UC or IBDU \[there will be 2 control groupControl groupThe group a new treatment is measured against.Read more →: non-IBD (undergoing colonoscopy but found not to have IBD; and healthy (no GI symptoms, so not required to have colonoscopy; could be family members)\]
  • +For UC: Remission-mild-moderate disease: Mayo score \<10
  • +Clinical indication for sedated colonoscopy
  • +Disease location: E2-E4
  • +Stable treatment (not on steroids; biologics or immunomodulator not changed in last month)
  • +High likelihood that patients will be able to collect all samples and provide all data

Exclusion

  • Use of antibiotics for a week or more over the last 3 months
  • Use of probiotics or prebiotics at pharmacological doses (adding fibre sources to food or probiotics in yogurt, for example, are allowed)
  • Documented enteric infection during the 3 months prior to endoscopy
  • Presence of non-IBD bowel conditions (e.g., celiac), anatomical or mucosal abnormalities, motility disorder
  • Presence of a systemic disease requiring treatment (cancer, ischemic heart disease, kidney failure, etc)
  • Proctitis (E1)
  • Systemic steroids (above 10 mg/day of Prednisone)
  • Topical therapy within 1 week of endoscopy
  • Recent change in IBD treatment (started biologics or IM over the last month)
  • Inability to understand or sign the consentInformed consentThe process of being told what taking part involves, then choosing freely.Read more →
  • Pregnancy or planning to become pregnant during the study
  • History of abdominal surgery, including appendectomy
5 concepts to explore on this page · up to 1,300 pointsTap any term to learn what it means.

In plain language

Assembled directly from this trial’s registry record. Every sentence traces to a field below — nothing here is generated or interpreted.

Learning 
What this study is

This study is investigating how something functions in the body, rather than testing a treatment directly.

This study is not organised into the usual phase numbers — that is common for device, behavioural, and diagnostic research.

From the trial registry

Built from these fields:

  • designModule.designInfo.primaryPurpose
  • designModule.phases
Who receives what

There are 4 groups in this study.

Group A, the placeboPlaceboA dummy treatment with no active medicine, used for comparison.Read more → group, receives Placebo ComparatorControl groupThe group a new treatment is measured against.Read more →: RandomizedRandomisedWhich group you go into is decided by chance, not by you or your doctor.Read more → pectin diet.

Registry label: A: Randomized pectin diet

Group B, the placebo group, receives Randomized B-fructan diet.

Registry label: B: Randomized B-fructan diet

Group C receives Personalized pectin diet.

Registry label: C: Personalized pectin diet

Group D receives Personalized B-fructan diet.

Registry label: D: Personalized B-fructan diet

From the trial registry

Built from these fields:

  • armsInterventionsModule.armGroups[].label
  • armsInterventionsModule.armGroups[].type
  • armsInterventionsModule.armGroups[].interventionNames
How the study is run

Which group you would be placed in is decided by chance, like a coin flip — not by you and not by your doctor.

Neither you nor the study team would know which group you are in until the study ends.

From the trial registry

Built from these fields:

  • designModule.designInfo.allocation
  • designModule.designInfo.maskingInfo.masking
Is there a placebo?

One group receives a placeboPlaceboA dummy treatment with no active medicine, used for comparison.Read more → — a dummy treatment with no active medicine in it.

From the trial registry

Built from these fields:

  • armsInterventionsModule.armGroups[].type
  • armsInterventionsModule.armGroups[].interventionNames
Who the study is looking for

The study lists an age range of 6 years to 39 years.

The study is open to people of any sex.

The study accepts healthy volunteersHealthy volunteerSomeone without the condition being studied who takes part anyway.Read more → as well as people with the condition.

These are the criteria the study lists. Only the trial siteTrial siteA hospital or clinic where a study is actually run.Read more → can decide whether someone can take part.

From the trial registry

Built from these fields:

  • eligibilityModule.minimumAge
  • eligibilityModule.maximumAge
  • eligibilityModule.sex
  • eligibilityModule.healthyVolunteers
How big and how long

The study aims to enrol about 600 people.

The study is currently expected to finish around December 2025.

The main measurement is taken over: 4 weeks.

From the trial registry

Built from these fields:

  • designModule.enrollmentInfo.count
  • statusModule.completionDateStruct.date
  • outcomesModule.primaryOutcomes[].timeFrame
What the study measures

Diet tolerability — measured over 4 weeks.

From the trial registry

Built from these fields:

  • outcomesModule.primaryOutcomes[].measure
  • outcomesModule.primaryOutcomes[].timeFrame

Source: NCT05615779 on ClinicalTrials.gov. The full registry text is further down this page — this summary never replaces it.

Not medical advice. What do these terms mean?

What is being tested — in plain terms

About Placebo Comparator: Randomized pectin dietOther

UC and healthy control participants randomized to receive recommendations provided by a dietician increasing consumption of foods high in pectin

From the trial registry — its own words, unedited.

What a other is here: An intervention the registry did not place in another category.

Read the full explanation → · in clinical review

About Randomized B-fructan dietOther

UC and healthy control participants randomized to receive recommendations provided by a dietician increasing consumption of foods high in B-fructan

From the trial registry — its own words, unedited.

What a other is here: An intervention the registry did not place in another category.

Read the full explanation → · in clinical review

About Personalized pectin dietOther

UC and healthy control participants to receive recommendations provided by a dietician increasing consumption of foods high in pectin based on personal host (biopsy) and microbe (stool) response at baseline

From the trial registry — its own words, unedited.

What a other is here: An intervention the registry did not place in another category.

Read the full explanation → · in clinical review

About Personalized B-fructan dietOther

UC and healthy control participants to receive recommendations provided by a dietician increasing consumption of foods high in B-fructan based on personal host (biopsy) and microbe (stool) response at baseline

From the trial registry — its own words, unedited.

What a other is here: An intervention the registry did not place in another category.

Read the full explanation → · in clinical review

Common questions

Answered from this trial’s registry record. Where the record doesn’t say, these answers say so rather than filling the gap.

Am I eligible for this trial?

Only the trial siteTrial siteA hospital or clinic where a study is actually run.Read more → can decide whether someone can take part. Concord cannot make that determination, and neither can any tool that has not examined you.

What the study lists: an age range of 6 years to 39 years.

The full inclusionInclusion criteriaThe things you must have or be for a study to consider you.Read more → and exclusion criteriaExclusion criteriaThe things that would prevent someone from taking part.Read more → are published on this page, exactly as the study team wrote them.

The useful next step is to bring this trial to your doctor. Answering a few questions first gives them something concrete to review.

From the trial registry
  • eligibilityModule.minimumAge
  • eligibilityModule.maximumAge
  • eligibilityModule.eligibilityCriteria
Is there a placebo?

Yes. This study includes a placeboPlaceboA dummy treatment with no active medicine, used for comparison.Read more → group — a dummy treatment with no active medicine in it.

From the trial registry
  • armsInterventionsModule.armGroups[].type
Would I know which treatment I am getting?

Neither you nor the study team would know which group you are in until the study ends.

Which group you would be placed in is decided by chance, like a coin flip — not by you and not by your doctor.

From the trial registry
  • designModule.designInfo.maskingInfo.masking
  • designModule.designInfo.allocation
Who can join?

The study lists an age range of 6 years to 39 years.

It is open to people of any sex.

It accepts healthy volunteersHealthy volunteerSomeone without the condition being studied who takes part anyway.Read more → as well as people with the condition.

Only the trial siteTrial siteA hospital or clinic where a study is actually run.Read more → can confirm whether a particular person can take part.

From the trial registry
  • eligibilityModule.minimumAge
  • eligibilityModule.maximumAge
  • eligibilityModule.sex
  • eligibilityModule.healthyVolunteers
How long would this take?

The study's main measurement is taken over: 4 weeks.

The study as a whole is currently expected to finish around 2025-12-01.

How long any one person takes part can differ from the study length. The study team can tell you what the schedule looks like in practice.

From the trial registry
  • outcomesModule.primaryOutcomes[].timeFrame
  • statusModule.completionDateStruct.date
How many people are taking part?

The study aims to enrol about 600 people.

From the trial registry
  • designModule.enrollmentInfo.count
Where is this happening?

This study lists 2 locations, including: Edmonton, Alberta, Canada; Winnipeg, Manitoba, Canada.

Sites can open and close during a study, so confirm with the team before travelling.

From the trial registry
  • trial_locations

About This Trial

This study aims to examine patient tolerability of personalized dietary fibre consumption recommendations (high-pectin diet versus high-B-fructan diet based on personalized responses), provided by an IBD dietician, based on our novel translational research findings.

Think this trial might be right for you?

Complete a quick intake form and we will match you with this and other relevant trials based on your medical profile.

See if this trial could fit you

This page is for informational purposes only and does not constitute medical advice. Clinical trial eligibility can only be determined by the trial site after proper screening. Trial information is sourced from ClinicalTrials.gov and may not reflect the most current status. Always consult your healthcare provider before making decisions about clinical trial participation.